Fund moves
10.0%Stake · was 10.0%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
GOVX · NASDAQ · Pharmaceutical Preparations
Geovax Labs (GOVX) · oqro.io/stocks/GOVX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.91−0.08 (−4.02%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day, not a live quote
No open-market purchase by an insider of Geovax Labs was filed in the last 90 days. The latest on record was on Aug 8, 2025.
Since 2007, Geovax Labs insiders reported 82 open-market purchases and 32 sales on Forms 4 and 5, with purchases in 12 different years, most recently 2025.
No open-market sale by an insider of Geovax Labs (GOVX) was filed with the SEC in the last 90 days.
No trade in Geovax Labs (GOVX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−99.2% (−$246.97) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $248.88 on Nov 19, 2025 to $1.91 on Nov 19, 2026 (−99.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Smyrna, Ga.
Last 12 months
−99.2%
Market value
$1.04M
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 176K shares sold short (32.3% of shares outstanding), −34.9% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$0
Year earlier: $0
Free cash flow, last 12 months
−$16.5M
This quarter −$4.34M, a year earlier −$6.21M
Net debt
—
Debt —, cash $2.15M, at Sep 30, 2026
Net income, last 12 months
−$18.3M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Jul 27, 2026.
Revenue, fiscal 2025
$2.49M
−37.1% vs the year before
Net income, fiscal 2025
−$21.5M
A loss for the year
Shares outstanding
544K
As of Nov 12, 2026
Reverse split 1-for-24 took effect Nov 11, 2026. Calendar
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Insider buying
Traded Aug 7, 2025 · filed 1 day later
Since the trade −99.5% · S&P 500 +13.2% · to Nov 19
Geovax Labs's Chief Medical Officer paid $742 out of pocket for Geovax Labs shares. Shares held went up 46% with this purchase.
Insider buying
Traded Apr 10, 2025 · filed 1 day later
Since the trade −99.7% · S&P 500 +36.5% · to Nov 19
A Geovax Labs director paid $9.8K out of pocket for Geovax Labs shares. 3 other people at Geovax Labs bought some too, in the same month. Shares held went up 713% with this purchase.
Insider buying
Traded Apr 10, 2025 · filed the same day
Since the trade −99.7% · S&P 500 +36.5% · to Nov 19
Geovax Labs's VP, Business Development paid $5.9K out of pocket for Geovax Labs shares. 3 other people at Geovax Labs bought some too, in the same month. Shares held went up 3141% with this purchase.
Insider buying
Traded Apr 1, 2025 · filed the same day
Since the trade −99.7% · S&P 500 +27.6% · to Nov 19
The CEO of Geovax Labs paid $11K out of pocket for Geovax Labs shares. 3 other people at Geovax Labs bought some too, in the same month. Shares held went up 38% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last results
Jul 27, 2026
More than 30 days ago
Next results, expected
Not announced
Purchases after results
42%
33 of 79 insider purchases since 2008 came within 30 days after a results announcement
From Geovax Labs's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Geovax Labs's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Insiders of Geovax Labs reported 82 open-market purchases and 32 sales since 2007; purchases in 12 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $35K5×5 trades | — |
| 2024 | $41K4×4 trades | — |
| 2023 | $58K6×6 trades | — |
| 2022 | $39K6×6 trades | — |
| 2020 | $1.23M6×6 trades | — |
| 2015 | $14K6×6 trades | — |
| 2012 | $30K2×2 trades | — |
| 2011 | $225K6×6 trades | — |
| 2010 | $190K37×37 trades | $104K15×15 trades |
| 2009 | $7K1×1 trade | $552K17×17 trades |
| 2008 | $9.8K1×1 trade | — |
| 2007 | $15K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Top officer leaving
“Resignation of Chief Financial Officer On November 13, 2026, Mark W.”
8-K on sec.govTop officer leaving
“Compensatory Arrangements of Certain Officers (b) Termination of President and Chief Executive Officer On November 5, 2026, David A.”
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govSaid its annual or quarterly report would be late
“GeoVax Labs, Inc. (the “Company”) has determined that it will not be able to file its Annual Report on Form 10-K for its fiscal year ended December 31, 2025 by March 31, 2026, the original due date for such filing, without unreasonable effort or expense, due to delays in compiling and reviewing certain information to be included in the Form 10-K. The Company expects to file the Form 10-K within the extension period o”
NT 10-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 4,000 words.
GeoVax is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax’s primary near-term strategic development priority is GEO-MVA, an MVA-based vaccine candidate for mpox and smallpox. GEO-MVA is being advanced on an expedited regulatory pathway in Europe and. is intended to address a documented global supply constraint for orthopoxvirus vaccines. The Company believes GEO-MVA is well-positioned to support both civilian public health needs and broader preparedness and biodefense objectives. The advancement of GEO-MVA represents the Company’s most near-term opportunity to achieve regulatory approval and potential commercialization.
And 1 more heading in the filing.
Source: SEC EDGAR, Form 10-K filed Apr 15, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: about 3.1 million shares a week traded away from the exchanges over the latest 4 published weeks, 97 thousand of them on ATS. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (23.3%), ONECHRONOS (11.1%), INTELLIGENT CROSS LLC (10.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others.
Latest annual report filed Apr 15, 2026, compared with the one filed Mar 27, 2025. Read the filing
We are not currently a party to any material legal proceedings. We may from time to time become involved in various legal proceedings such as those arising in the ordinary course of business.
Source: SEC EDGAR, Form 10-K filed Apr 15, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.